Why is heparin a powerful endogenous anticoagulant

Modern anticoagulation

  • 1.

    Agnelli G, Prandoni P, Santamaria MG et al. (1999) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345: 165

    Article Google Scholar

  • 2.

    Bauersachs RM, Lindhoff-Last E, Wolff U, Ehrly AM (1998) Current management of deep vein thrombosis. Med World 49: 194

    Google Scholar

  • 3.

    Breddin HK (1997) Heparinoids. Hemostaseology 17: 49-53

    Google Scholar

  • 4.

    Breddin HK (1999) Low molecular weight heparins in the prevention of deep vein thrombosis in general surgery. Semin Thromb Haemostas 25 (Suppl): 83-89

    CAS Google Scholar

  • 5.

    Breddin HK (2000) Recombinant hirudin or low molecular weight heparin in the prophylaxis and therapy of arterial and venous thromboses. In: Encke A, Breddin HK (Ed) The venous thrombosis. Schattauer, Stuttgart New York, pp. 205-210

  • 6.

    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV (2001) Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 344: 626-631

    CASPubMed Google Scholar

  • 7.

    Chong BH (2003) Heparin-induced thrombocytopenia. J Thromb Haemost 1: 1471-1478

    Google Scholar

  • 8.

    Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 18: 349-355

    CASPubMed Google Scholar

  • 9.

    Crowther MA (2003) Oral-direct thrombin inhibitors. In: Sasahara AA, Loscalzo J (eds) New therapeutic agents in thrombosis and thrombolysis. Marcel Dekker, New York Basel, pp 265-272

  • 10.

    EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 342: 1255-1262

    PubMed Google Scholar

  • 11.

    Hach-Wunderle V, Bauersachs R, Landgraf H, Schellong S, Schweizer J, Wuppermann T (2002) Guidelines of the German Society for Angiology: Venous thromboembolism. VASA S60: 1

    Google Scholar

  • 12.

    Harrington RA, Maraganore JM (2003) Clinical development of bivalirudin. In: Sasahara AA, Loscalzo J (eds) New therapeutic agents in thrombosis and thrombolysis. Marcel Dekker, New York Basel, pp 217-240

  • 13.

    Hirsh J, Dalen JE, Anderson RD et al. (2001) Oral anticoagulants: mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 119: 64S-94S

    CASPubMed Google Scholar

  • 14.

    Hoppensteadt DA, Fareed J, Kaiser B (2003) Tissue Factor Pathway Inhibitor: potential implications in the treatment of cardiovascular disorders. In: Sasahara AA, Loscalzo J (eds) New therapeutic agents in thrombosis and thrombolysis. Marcel Dekker, New York Basel, pp 281-300

  • 15.

    Hyers ™, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG (2001) Antithrombotic therapy for venous thromboembolic disease. Chest 119: 176S-193S

    CASPubMed Google Scholar

  • 16.

    Kearon C, Ginsberg JS, Kovacs M et al. for the ELATE Investigators (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349: 631-639

    ArticleCASPubMed Google Scholar

  • 17.

    Kearon C, Ginsberg JS, Kovacs M et al. (2003) Influence of thrombophilia on efficacy of warfarin for prevention of recurrent venous thromboembolism: results from a randomized trial. J Thromb Haemostas 1 (Suppl): OC002

    Google Scholar

  • 18.

    Kearon C, Gent M, Hirsh J et al. (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340: 901-907

    CASPubMed Google Scholar

  • 19.

    Lewis BE, Walenga JM (2003) Clinical use of argatroban. In: Sasahara AA, Loscalzo J (eds) New therapeutic agents in thrombosis and thrombolysis. Marcel Dekker, New York Basel, pp 185-200

  • 20.

    Mattsson C, Menschik-Lundin A, Nylander S, Gyzander E, Deinum J (2001) Effect of different types of thrombin inhibitors on thrombin / thrombomodulin modulated activation of protein C in vitro. Thromb Res 104: 475-486

    ArticleCASPubMed Google Scholar

  • 21.

    Moons AH (2003) Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor / factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 41: 2147-2153

    ArticleCASPubMed Google Scholar

  • 22.

    Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S (2002) Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 87: 7-12

    Google Scholar

  • 23.

    Prandoni P, Lensing AW, Prins MH et al. (2002) Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137: 955-960

    Google Scholar

  • 24.

    Ridker P et. al for the PREVENT Investigators (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348: 1425-1434

    CASPubMed Google Scholar

  • 25.

    Salem DN, Daudelin HD, Levine HJ, Pauker SG, Eckman MH, Riff J (2001) Antithrombotic therapy in valvular heart disease. Chest 119: 207S-219S

    ArticleCASPubMed Google Scholar

  • 26.

    Schulman S, Rhedin AS, Lindmarker P et al. For the Duration of Anticoagulation Trial Study Group (1995) Comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332: 1661-1665

    ArticleCASPubMed Google Scholar

  • 27.

    Schulman S, Granqvist S, Holmström M et al. The Duration of Anticoagulation Trial Study Group (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism in venous thromboembolism. N Engl J Med 336: 393-398

    CASPubMed Google Scholar

  • 28.

    The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323: 1505-1511

    PubMed Google Scholar

  • 29.

    Walenga JM, Jeske WP, Fareed J, Samama MM (2003) Development of a synthetic heparin pentasaccharide as an antithromboti agent. In: Sasahara AA, Loscalzo J (eds) New therapeutic agents in thrombosis and thrombolysis. Marcel Dekker, New York Basel, pp 241-264

  • 30.

    Weiler H, Isermann BH (2003) Thrombomodulin. J Thromb Haemost 1: 1515-1524

    Google Scholar